Butyrylcholinesterase (BChE) inhibitors were identified from a collection containing cinchonine, cinchonidine and synthetic derivatives, and further characterized using cytotoxicity and molecular docking studies. The most active ones were: (10≡)-10,11-dibromo-10,11-dihydrocinchonidine (11), a competitive inhibitor with K i = 3.45±0.39 µM, and IC 50 BChE = 9.83±0.30 µM / human (h)BChE = 34.47±4.63 and O-(trimethylsilyl)cinchonine (15), a mixed inhibitor with K iuc = 1.73±0.46 µM and K ic = 0.85±0.26 µM, and IC 50 BChE = 0.56±0.14 µM / hBChE = 0.24±0.04. In cytotoxicity experiments, ≥80% of the cells remained viable when exposed to concentrations of up to 80 µM of both inhibitors in four different cell lines, including neurons. Due to the bulkier trimethylsilyl side group of 15, it covered the active site of hBChE better than 11 with an OH-group while not being able to fit into the active site gorge of hAChE, thus explaining the selectivity of 15 towards hBChE. Figure 1: Active compounds against equine BChE, as well as the original alkaloids (coded 1 and 3) . After the original alkaloids, compounds are organized according to their BChE inhibitory activity (inhibition percentage) measured at 10 M. (Derivatives of cinchonidine: CD, and cinchonine: CN)
Alzheimer's disease (AD) therapy currently consists of two types of drugs: the cholinesterase inhibitors donezepil, galanthamine and rivastigmine, and an N-methyl-D-aspartate (NMDA) receptor antagonist, memantine. Many other approaches have been explored (i.e. β-and γ-secretase inhibitors/modulators, antifibrillization agents, statins, muscarinic M1 agonists, and anti-inflammatory compounds) [1] , but cholinesterase inhibitors have remained the most successful and most widely used drug class for the treatment of AD. Although the cholinesterase inhibitors used for AD therapy primarily target acetylcholinesterase (EC 3.1.1.7) (AChE), the main enzyme hydrolyzing acetylcholine (ACh), there is evidence suggesting that butyrylcholinesterase (EC 3.1.1.8) (BChE) may have a crucial role in the progression of AD. This includes the facts that i) in the AD brain the activity of BChE remains the same or even increases while the activity of AChE decreases progressively, thus giving BChE a more important role in hydrolysing ACh [2, 3] , ii) individuals carrying a less active genetic variant of BChE (Ala539Thr) seem to have a lower susceptibility for developing AD [4] , and iii) in rodents, treatment with selective BChE inhibitors has been shown to augment learning and lower Aβ oligomer deposits without the classic adverse actions seen upon treatment with AChE inhibitors [5] . In view of these, targeting BChE seems to be as important, if not more important, than targeting AChE, and may offer an advantage in future AD pharmacotherapy.
The bark of the cinchona tree (Cinchona spp., family Rubiaceae) has traditionally been used to treat fever, cardiac arrhythmias and specially malaria [6] . This ethnobotanical use is connected to alkaloids, the major ones being quinine, quinidine, cinchonidine and cinchonine. In line with prior results [7,8a] , quinidine was identified as a selective inhibitor of the equine serum BChE (IC 50 of 7.37 µM), whereas quinine showed 25% inhibition of equine BChE and 16% inhibition of electric eel AChE at 8.4 µM [8b]. Taking into account that quinidine and quinine can inhibit cholinesterases, in the present contribution we have investigated the less studied cinchonidine and cinchonine, together with a small collection of 21 compounds synthetically derived from these two alkaloids. This library has previously been studied for antibacterial and anti-biofilm activity by our group [8c]. In this contribution we explored the effect of chemical modification on cholinesterases activity with an emphasis on selective inhibition of human BChE.
The screening was done at 10 µM and the theoretical hit limit was set at 13.7% (3xSD). Four compounds qualified as BChE inhibitors ( Supplementary Table S1 ); three cinchonidine derivatives with moderate activity, 9, 11 and 20, and a cinchonine derivative with high activity, 15 (Figure 1 ). Given the high structural similarities between BChE and AChE, inhibitors of one enzyme are typically tested in the other one to assess possible "off-target" effects. Two compounds were found to be active against AChE; 18 (54% at 10 µM) and 11 (26% at 10 µM). Compound 11 (a mixture of two diastereoisomers) was also one of the identified BChE inhibitors. Comparing the active derivatives to the original alkaloids ( Figure 1 ) it can be seen that, in the case of cinchonidine (1), small changes to the hydroxyl group increased the activity of the compound from showing no activity (1) to 35% inhibition of the equine BChE (as in 20 via an addition of a methyl group) or even to 40% BChE inhibition (as in 9, via oxidation of the hydroxyl group to a ketone). Moreover, bromide substitutions at the ethylene moiety of 1 increased the activity to 48% inhibition (11) .
At this point, only the two most active BChE inhibitors were further characterized. For 11 the IC 50 BChE value was determined to be 9.83 ± 0.30 µM and IC 50 AChE value was 25.4 ± 0.10, while 15 had an IC 50 BChE value of 0.56 ± 0.14 µM, but showed no activity against AChE up to a concentration of 250 µM ( Table 1 ). The IC 50 BChE of cinchonidine (1) and cinchonine (3) were tested for comparison purposes, as they are the parent molecules of 11 and 15, and their potencies were found to be 76.0 ± 4.5 µM and 117.2 ± 25.4 µM, respectively. The found BChE inhibitors showed differences in their inhibition mechanism (Supplementary Figure  S1 ). While 11 displayed a competitive inhibition mechanism with a K i of 3.45 ± 0.39 µM, 15 appeared to have a mixed inhibition mechanism with K i values of 0.85 ± 0.26 (competitive, K ic ) and 1.73 ± 0.46 (uncompetitive, K iuc ). The two active compounds were further tested on the human cholinesterases (Table 1 ) and hBChE IC 50 values were determined to be 34.5 ± 4.6 µM and 0.24 ± 0.04 µM for 11 and 15, while hAChE IC 50 values were 115.1 ± 28.5 µM and >250 µM, respectively. The selectivity of 11 towards BChE, when compared with AChE was two-fold with a higher activity against the equine BChE than the hBChE. The most active BChE inhibitor was 15, a cinchonine derivative with a trimethylsilyl substitution at the hydroxyl group, which displayed over 400 times more selectivity towards BChE than AChE and it was two-fold more active against hBChE than equine BChE. Thus selective BChE inhibitors were obtained by making minor modifications of both parent alkaloids. Seemingly, the inhibition was stereoselective because the isomer (16) of the most active compound (15) did not inhibit BChE.
Possible cytotoxic effects of compounds 11 and 15 were tested in four different cell lines; GT1-7 [9a], HL, HepG2 and Caco-2 cells, as described by Karlsson et al. [9b] . Compound 11 decreased cell viability to around 60% at 100 µM in HL and Caco-2 cells after 24 h, but for the most potent compound (15) , registered cell viability values were 80% or higher in all the cells lines within the whole concentration range (up to 100 µM) (Supplementary Figure S2 ).
It is known that, apart from enzyme and substrate concentrations, also the reaction order in the assay and pre-incubation with the enzyme affects the potency of some types of inhibitors [10a] . Timedependent inhibitors are sometimes considered disadvantageous as their activity may often be due to factors like aggregation, covalent binding or electrophilic protein reactions [10b]. However, preincubation trial with 15 did not show a time-dependent inhibition as there was no apparent change in the potency (IC 50 BChE) after 30 (0.58 ± 0.02 µM) and 60 minutes (0.64 ± 0.04 µM) incubation with the enzyme, as compared with no pre-incubation (0.56 ± 0.14 µM). Physostigmine, which is known to be a competitive slow-binding inhibitor, was used for comparison and showed clear improvement in potency when pre-incubating with equine BChE. Changing the reaction order from starting the reaction with the enzyme to the substrate significantly improved the IC 50 BChE for physostigmine from 2.04 ± 0.30 µM to 0.075 ± 0.021 µM and improved further with an incubation of 30 (0.010 ± 0.001 µM) and 60 minutes (0.006 ± 0.002 µM), in line with previous results of our group for the inhibitory effect of physostigmine against AChE [10a] .
The Principal Component Analysis (PCA)-based chemical space navigation concept ChemGPS-NP [10c,d] was used to characterize the chemical space populated by this chemical collection. This is a freely available chemography tool especially suitable for natural products. It was seen that this library contains molecules of various sizes spanning towards the positive and negative directions of PC1; they are all aromatic (positive PC2), lipophilic (positive PC3) and on the rigid side (negative PC4) (Figure 2 and Supplementary Table  S2 ). The active compounds (red dots) seemed to be located in a well-defined area of the chemical space, when compared with nonactives (white dots). Such a privileged region seems to be defined by small molecular sizes, high aromaticity, a moderate lipophilicity and restricted flexibility ( Figure 2 ). Two non-active compounds located in the closest vicinity to the actives were: 16 with BChE inhibition of 12%, which is the cinchonidine isomer of 15, and 23 with BChE inhibition of 10%, the cinchonine isomer of 20, with both 15 and 20 being active hits (structures are found in Supplementary Table S1 ).
A.
B. Figure 2A while PC4 is visualized instead of PC3 in Figure 2B . Recently Nawaz et al. reported the cholinesterase inhibition of quinine, along with cinchonidine and a group of derivatives containing an anthracene moiety [11] . Although quinine and cinchonidine were found active, the most potent compound was identified as a cinchonidine derivative, with an IC 50 BChE value of 0.34 µM (K i = 0.4 µM). These inhibitors published by Nawaz et al. [11] (black dots in Figure 2 ) differ from our compounds in their molecular size (positive PC1), as well as being more aromatic (positive PC2) and lipophilic (positive PC3) (mostly due to the additional anthracene moiety) (Figure 2A and Supplementary Table  S2 ). However, all compounds share the same degree of rigidity (negative PC4) ( Figure 2B ). Nawaz et al. had concluded in their study that cinchonidine alkaloids containing a quaternized quinuclidine nitrogen and additional aromatic rings enhance the selective inhibition of BChE [11] . We compared our active BChE inhibitors (9, 11, 15 and 20) with those included in the study of Nawaz et al. [11] , and observed that although they lack any additional aromatic rings, they do have side chain substitution at the hydroxyl group, as do the compounds reported by Nawaz et al.
The crystal structure of hBChE (1P0I) was used as the target for docking the BChE active inhibitors 11 and 15. The active site of the hBChE consists mainly of residues ASP70, TRP82, GLY116, GLY117, GLU197, SER198, ALA199, TRP231, LEU286, SER287, VAL288, TYR332 and HIS438 [13a] . Conserved water molecules within the active site gorge are shown to influence the binding of inhibitors with the enzyme and mediate hydrogen bonding interactions with the active site residues. In this case, conserved water molecules W736, W786, W811, W825, W839, W875, W910, W919, W1042, W1076 and W1177 are depicted as W1, W2, W3, W4, W5, W6, W7, W8, W9, W10 and W11, respectively. To exemplify the potential binding of compound 11, one of the diastereomers was arbitrarily selected for the docking study. Molecular docking results of 11 and 15 in hBChE are shown in Figure 3A -B. Compound 11 shows the H-bond interaction with GLY116 and SER198 and also with a water molecule W9 ( Figure  3A) , while 15 may form π-π stacking interactions with TRP82 ( Figure 3B ). Compound 15 with the bulky trimethylsilyl group covers the active site gorge more prominently, showing a good binding affinity as compared with 11 ( Figure 3A) , and may form ππ stacking interactions with TRP82 ( Figure 3B) , as was the case with the most active compound in the study by Nawaz et al. [11] . In the case of hAChE, we have used the recently solved hAChE crystal structure (4EY7) for our docking studies. The active site of hAChE consists mainly of residues TYR72, TRP86, TYR124, GLU202, SER203, ALA226, PHE295, TYR337, TYR341 and HIS447 [13b]. Conserved water molecules W728, W737, W856, W931, W952, W953 and W954 are depicted as W1, W2, W3, W4, W5, W6 and W7, respectively. The active site regions of hAChE and hBChE differ and the hAChE has a smaller area towards its gorge opening with respect to that of hBChE. Both compounds showed less binding affinity towards hAChE in comparison with that of hBChE. The docking scores of the compounds within the active sites of hBChE and hAChE were −8.81 and −6.51 for 11 and −7.55 and −4.34 for 15, respectively. Better binding in hAChE was showed by the diastereomer used for the docking studies of 11, which may form π-π stacking interaction with TYR341 ( Figure 3C ), while 15 showed a low binding score as it is not able to enter the active site gorge completely ( Figure 3D ). This might be due to its bulkier size and highly non-planar docking conformation, which will deter its entering the gorge site for its favourable binding as revealed in Figure 3D [13b]. Thus, this investigation paves the way to future structure optimization aimed at producing more selective BChE inhibitors, based on natural chemical templates (cinchonidine and cinchonine) that have long been used in ethnopharmacological preparations and proven to be safe.
Experimental
Chemical library: The commercial sources or the methods utilized for the synthesis of compounds are included in Supplementary Table  S1 . The compounds 11 and 15 were prepared according to reported methods [13c,d,14a] . Compounds were dissolved in dry-DMSO in cryogenic tubes (external threaded polypropylene vials with plug seal caps) to a final concentration of 20 mM, after which they were maintained at -20°C. The compounds were diluted in Tris-HCl 50 mM pH 8 to final concentrations before using them in the bioassays. 
Chemical space exploration:
ChemGPS-NP web [10c,d] (name refers to the program being a chemography tool applicable to Natural Products) (http://chemgps.bmc.uu.se/batchelor/queue.php? show=submit) was used to obtain principal components as described in Karlsson et al. [9b] . Compounds were analysed in a 3D graph using Grapher (Mac OS X v10.5, US).
Docking analysis of molecules using Glide: Molecular docking of 11 and 15 was done in hBChE crystal structure, PDB code 1P0I (resolution 2 Å) [13a] , and hAChE crystal structure, PDB code 4EY7 (resolution 2.35 Å) [13b], using Glide software [15] . The proteins were prepared using the Protein Preparation Wizard in Schrödinger. In this, the bond orders are assigned, hydrogen atoms are added, atom types are defined, and the charge and protonation states are also corrected. The protein was energy minimized up to 0.30 Ǻ and all the water molecules in the grid measuring 5 Ǻ beyond hetero groups were deleted. The ligand structures were drawn in Maestro. The ligands (compound 11 and compound 15) were prepared using Ligprep module with MMFF force field, and the grid was defined using the centroid of the active site residues.
The option to dock flexibly with the extra precision (XP) mode was selected for our docking studies [15] .
